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Fluorosis is caused by excess of fluoride intake over a long period of time. Aberrant change in the Runt-related transcription factor
2 (RUNX2) mediated signaling cascade is one of the decisive steps during the pathogenesis of fluorosis. Up to date, role of fluoride
on the epigenetic alterations is not studied. In the present study, global expression profiling of short noncoding RNAs, in particular
miRNAs and snoRNAs, was carried out in sodium fluoride (NaF) treated human osteosarcoma (HOS) cells to understand their
possible role in the development of fluorosis. qPCR and in silico hybridization revealed that miR-124 and miR-155 can be directly
involved in the transcriptional regulation of Runt-related transcription factor 2 (RUNX2) and receptor activator of nuclear factor
𝜅-B ligand (RANKL) genes. Compared to control, C/D box analysis revealed marked elevation in the number of UG dinucleotides
and D-box sequences in NaF exposed HOS cells. Herein, we report miR-124 and miR-155 as the new possible players involved in
the development of fluorosis. We show that the alterations in UG dinucleotides and D-box sequences of snoRNAs could be due to
NaF exposure.
1. Introduction
The global prevalence of fluorosis is a matter of great
concern. Chronic exposure of high concentration of fluoride
(>1.5mg/L) may result in skeletal and dental deformities [1].
At present, 25 countries around the world have endemic to
fluorosis [1]. In India, the health of approximately 62 million
people is at risk due to high concentration of fluoride in
drinking water/diet and so forth [1]. Preventive measures
against fluorosis rely on the intake of low fluoride diet/water
to reduce the ingestion of fluoride inside the body [1, 2].
However, these preventive measures were not successful in
most of the underdeveloped and developing counties due to
high cost associated with the defluoridation techniques [1, 2].
Available drug therapy against fluorosis includes supplemen-
tations with aluminum, magnesium, calcium, amino acid,
and vitamins (C, D, and E) [1, 3]. These supplementations
can stimulate calcium bone mineralization, activation of
phagocytes/osteoclasts and antioxidant enzymes to combat
oxidative stress induced by fluoride [2, 3]. However, the
therapeutic effects incurred due to these supplements are
unstable and reversible [2, 3].
No concurrent therapies are available against fluorosis
due to limited information on the expression of aberrant
posttranscriptional cascades involved in the development of
skeletal and dental deformities [3]. Intake of high concen-
tration of fluoride is reported to impede skeletal forma-
tion and remodeling processes due to failure in the signal
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transduction between the osteoblast and osteoclast cells
through receptor activator of nuclear factor 𝜅-B ligand
(RANKL), receptor activator of nuclear factor 𝜅-B (RANK),
and osteoprotegerin (OPG) system [4]. RANKL/RANK
signaling positively regulates osteoclast differentiation and
promotes bone remodeling, whereas OPG/RANKL signal-
ing protects the skeleton from the bone [4–7]. Aberrant
variations in the RANKL/RANK/OPG system limits the
availability of free calcium required for osteocalcin (bone
gamma-carboxyglutamic acid-containing protein; BGLAP)
mediated bone mineralization, leading to the excess of
fluoride deposition inside the bones [6, 8].
The research on posttranscriptional gene-expression reg-
ulation raveled the pivotal role of short noncoding RNAs
(miRNA, snoRNA, etc.) in the response of cell against envi-
ronmental factors. In particular the miRNAs are the deeply
investigated class of noncoding RNAs. But, limited reports
entail that miRNAs can regulate bone formation and remod-
eling processes [9–11]. miR-204 andmiR-211 were reported as
the negative regulators of the gene involved in osteoblast acti-
vation, RUNX2 [9]. Similarly, the RUNX2-targeting miRNAs
were reported to impede osteoblast differentiation [10, 11].
Thus, it is likely that miRNAs can be involved in the posttran-
scriptional regulation of other important signaling cascades
(e.g., RANKL/RANK/OPG system and BGLAP) required for
bone formation and remodeling processes. Less information
is available on the effects of environmental factors on short
noncoding RNAs, the small nucleolar RNAs (snoRNAs)
[12]. Small nucleolar RNAs (snoRNAs) are a group of small
RNA that principally regulate chemical alterations in other
noncoding RNAs such as transfer RNAs (tRNAs), ribosomal
RNAs (rRNAs), and small nuclear RNAs (snRNAs) [13].
snoRNAs are divided into two main classes depending upon
the presence of C/D box and H/ACA box sequences [13].
C/D box snoRNAs are primarily involved in 2󸀠-O-ribose
methylation, whereas H/ACA box snoRNAs are involved in
the pseudouridylation of noncoding RNAs [13].
Deleterious effects of fluoride on the expression levels of
noncoding RNAs have not been studied. Herein, for the first
time, we report a global expression profiling of noncoding
RNAs (miRNAs and small nucleolar RNAs (snoRNAs)) in
sodium fluoride (NaF) exposed human osteosarcoma (HOS)
cells. Compared to control, analysis usingAffymetrixmiRNA
3.0 array platform (5639 human probes) revealed differen-
tial expressions of signature miRNAs and snoRNAs after
sodium fluoride treatment (8mg/L and 20mg/L) to HOS
cells. Further validation using real time PCR illustrated the
upregulation ofmiR-124 andmiR-155, whereas the expression
levels of RANKL, BGLAP, and RUNX2 genes were decreased
in NaF treated cells. OPG, a soluble decoy of RANKL, was
upregulated in NaF treated cells. Data obtained from in
silico hybridization analysis revealed that miR-124 and miR-
155 could be directly involved in the posttranscriptional
regulation of RUNX2 and RANKL genes. Compared to the
terminal C/D box,microarray analysis revealedmoremarked
effect of fluoride exposure on the expression levels of internal
C/D boxes of snoRNAs. In addition, D-box, a pivotal element
in methylation process, was found to be strongly influenced
by NaF. Our results suggest the possible involvement of miR-
124 and miR-155 in the development of fluorosis. In addition,
high sensitivity of NaF to D-box of snoRNAs suggests the
posttranscriptional regulation of hypo/hypermethylated and
pseudourydilated rRNAs that could be involved in bone
formation and remodeling processes.
2. Material and Methods
2.1. Cell Lines. Human osteosarcoma (HOS) cell line was
purchased from National Centre for Cell Science (NCCS)
Pune, India. Cells were resuspended in Minimum Essential
Medium (MEM) supplemented with 10% fetal bovine serum,
100U/mL penicillin, 50 𝜇g/mL streptomycin, and 25 𝜇g/mL
Fungizone. Cells were maintained at 37∘C in a humidified
atmosphere with 5% CO
2
.
2.2. Cell Viability Assay. Cell viability was assessed using 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. Cells (10,000 cells/well) were seeded in a
96-well plate for 24 h. After 24 h of seeding, HOS cells
were exposed to different concentrations of NaF (10mg/L
to 250mg/L) and further incubated for 24 h. After 24 h of
exposure, MTT solution (5mg/L in PBS) (Invitrogen, USA)
was added and cells were incubated at 37∘C for 3 h. Media
were discarded and cells were resuspended in 200𝜇L of
DMSO (Sigma Aldrich, USA) and analyzed at 565 nm. Lethal
concentration 50 (LC
50
) of NaF was calculated using the dose
response curve analysis.
2.3. NaF Treatment. HOS cells were exposed to sublethal
concentrations (8mg/L (1/5th) and 20mg/L (1/2nd) of 24 h
LC
50
) of NaF (Sigma Aldrich, USA) for 30 days; subsequent
controls weremaintained. 50,000 cells/mLwere seeded in cell
flask, followed by the treatment of sodiumfluoride. Cells were
subcultured after 3 days and NaF treatment was given after
every passage and culture media change. Finally, cells were
harvested in Trizol reagent (Invitrogen, USA).
2.4. miRNAMicroarray. Total RNA was isolated using Abso-
lutely RNA Kit (Stratagene, USA), according to the manufac-
turer’s recommendations. Quality of RNA was checked using
Agilent Bioanalyzer 2100 (Agilent Technologies Inc., USA).
Affymetrix miRNA 3.0 array platform was used to elucidate
the variations in the expression profiles of 5639 human
noncoding mature RNA probes after NaF treatment to HOS
cells. Hybridizationwas carried out at 48∘C for 16 h at 60 rpm.
Probe intensities were measured using GeneChip Scanner
3000 7G (Affymetrix, USA). All the original microarray data
(CEL files) for the experiments was preprocessed using RMA
(Robust Multichip Average) algorithm that consists of three
steps: a background adjustment, quantile normalization, and
summarization. The raw data normalization has been per-
formed by selecting “organism human” in Expression Con-
sole tool. All above procedures were done by selecting default
RMA algorithm, data adjustment, and background correc-
tion (GABG) in Affymetrix Expression Console 1.2.1.20. Box
whisker plot (see Supplementary data; S1 available online
at http://dx.doi.org/10.1155/2015/274852) and quality control
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Table 1: qPCR primers.
Sr. number Gene name Primer Sequence (5󸀠-3󸀠)
miRNAs
1 miRNA-155 Forward primer TGTTAATGCTAATATGTAGGAG
2 miRNA-124 Forward primer GGCATTCACCGCGTGCCTTA
3 RUN48 Forward primer AGTGATGATGACCCCAGGTAACTC
Reverse primer CTGCGGTGATGGCATCAG
Genes
4 RUNX2 Forward primer GGCAGGCACAGTCTTCCC
Reverse primer GGCCCAGTTCTGAAGCACC
5 RANKL Forward primer TCGTTGGATCACAGCACATCA
Reverse primer TATGGGAACCAGATGGGATGTC
6 BGLAP Forward primer ATGAGAGCCCTCACACTCCTC
Reverse primer GCCGTAGAAGCGCCGATAGGC
7 OPG Forward primer CTGGAACCCCAGAGCGAAAT
Reverse primer GCCTCCTCACACAGGGTAAC
5 RPII (internal control) Forward primer GCACCACGTCCAATGACAT
Reverse primer GTGCGGCTGGTTCCATAA
6 HPRT (internal control) Forward primer ACGAAGTGTTGGATATAAGC
Reverse primer ATAATTTTACTGGCGATGTC
analyses were carried out using Expression Console software.
Normalized intensity files were exported from Expression
Consoles tool in txt format. In next step, all normalized exper-
imental data were imported in GeneSpring GX 12.5 software
for the differential miRNA expression, fold change analysis,
and cluster analysis. Statistical analysis was performed for
the identification of differentially expressed miRNA from
two groups (Dose 1/5 (8mg/L) versus control and Dose 1/2
(20mg/L) versus control) (Supplementary Table; S2). One-
way ANOVA method was applied for assessing the statis-
tically significant differentially expressed miRNAs for two
different treated experiment groups with reference to control.
The 𝑃 value cut-off 0.05 was considered statistically signifi-
cant. miRNA microarray data has been submitted in NCBI
GEO, accession number GSE57550.
2.5. In Silico Hybridization Analysis. mirTarBase and
miRANDA software were used to identify functionally vali-
dated targets of miR-124 and miR-155. Furthermore, differ-
entially expressed miRNAs were screened for their possible
putative targets using in silico hybridization analysis. Possible
binding sites of miR-124 and miR-155 with the RUNX2 and
RANKL were identified.
2.6. Real Time qPCR. Screened miRNAs and genes were val-
idated using quantitative qPCR. miRNAs were isolated using
mirPremier microRNA Isolation Kit (Sigma Aldrich, USA).
NaF exposed cells were lyzed using microRNA lysis buffer
supplemented with RNA binding solution. miRNAs were
isolated as per the instructions given in the manufactures
protocol. 500 ng of miRNA was converted to cDNA using
NCodeVILOmiRNAcDNASynthesisKit (Invitrogen,USA).
Relative quantification of miRNA was performed on Applied
Biosystems 7300 real time PCR system using EXPRESS
SYBRGreenER qPCR SuperMix containing universal reverse
primers (Invitrogen, USA) and forward customized primers
of miR-124/miR-155 (Table 1). RUN48 was used as internal
controls as described earlier [14]. Fold change was calculated
using ddCT method (2∧-ddCt).
For validation of genes, total RNA was isolated using Tri-
zol reagent. 2 𝜇g of total RNA was converted to cDNA using
High Capacity Reverse Transcription kit (Applied Biosys-
tems, USA). qPCR primers for RUNX2, RANKL, BGLAP,
and OPG were used as described earlier (Table 1) [15–17].
RNA polymerase II (RPII) and hypoxanthine phosphori-
bosyl transferase (HPRT) were used as internal controls as
described earlier [18]. Relative quantification was performed
on Applied Biosystems 7300 real time PCR system using
EXPRESS SYBR GreenER qPCR SuperMix. All the primers
were validated before relative quantification. Fold change was
calculated using ddCT method (2∧-ddCt).
2.7. C/D Box Analysis of snoRNA. Differentially expressed
snoRNAs obtained by microarray analysis were further ana-
lyzed for the expression levels of C/D boxes using an in silico
approach. Probes mapped on the array showed high length
variability encompassed in the range from 48 to 237 bp. This
great variability suggested partitioning the C/D box data set
on the basis of their length. Box plot (Supplementary data;
S3A) shows a statistical analysis of length outliers of C/D box
snoRNAs.The length outliers in snoRNAwere determined by
interquartile range method, described below:
Lower Limit = 𝑞
0.25
− 1.5 IQR,
Upper Limit = 𝑞
0.75
+ 1.5 IQR.
(1)
Lower and upper limits set for outlier detection were LL =
45.87 and UL = 112.87, respectively (please refer to supple-
mentary data; S3 for the details).
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Figure 1: LC
50
(24 h) of NaF against HOS cells. Graph represents the
cytotoxicity caused by sodium fluoride after 24 h of exposure.
3. Results
Cell viability was found to be decreased with increasing
concentrations of NaF. LC
50
(24 h) concentration of NaF
against HOS cells was found to be 40mg/L (Figure 1). Based
on these results, sublethal concentrations (8mg/L (1/5th) and
20mg/L (1/2nd) of 24 h LC
50
) of NaF were chosen for further
experiments.
The microarray experiment (Figure 2) was carried out
using two different test concentrations, that is, 8mg/L and
20mg/L of NaF. Out of 5,639 probes, each test concentration
displayed 128 differentially expressed miRNAs (𝑃 < 0.05).
Supplementary Table S2 displays representative miRNA sig-
natures which were differentially expressed in both the test
concentrations (𝑃 < 0.05). Further screening with one and
half fold change cut (FC ≥ 1.5) showed 82 and 62 differentially
expressedmiRNAs in 8mg/L and 20mg/L test concentrations
of NaF, respectively. In it, 56 and 21 miRNAs were found to
be upregulated in 8mg/L and 20mg/L of test concentrations,
respectively.
mirTarBase andmiRANDA software were used to under-
stand the possible involvement of miRNAs in the regulation
of osteoclastogenic signaling pathway. In silico hybridization
revealed that seed regionsmiR-124 andmiR-155 can bindwith
the untranslated regions (UTRs) of the RUNX2 and RANKL
(Figure 3).Out of all the possible alignments ofmiR-124/miR-
155 with the RUNX2/RANKL, pairs depicting hybridization
with the conserved domains, good mirSVR and PhastCons
scores were selected using miRANDA software. Validation of
miRNAs using qPCR demonstrated that sublethal concentra-
tions of NaF can significantly (𝑃 < 0.05) upregulate miR-124
and miR-155 expressions in HOS cells (Figure 4). Compared
to the higher dose level (20mg/L) of NaF, expression levels
of miRNAs were more elevated in low dose level (8mg/L). At
lower dose level, fold change in the expression levels of miR-
124 and miR-155 was observed to be 3.24 (±0.13) and 4.03
(±0.3), respectively. At higher dose level, fold change in the
expression levels of miR-124 and miR-155 was observed to be
1.6 (±0.19) and 1.86 (±0.24), respectively.
Further validation through qPCR revealed that upregu-
lation of miR-124 and miR-155 led to the downregulation of
Runx2 (𝑃 < 0.05) in NaF treated HOS cells. At lower dose
level, fold change in the expression levels of the RUNX2 was
observed to be −3.25 (±0.27), whereas at higher dose level
the fold change was observed to be −2.15 (±0.13) (Figure 5).
Validation of other osteoblastic lineage markers (RANKL,
BGLAP, and OPG) through qPCR suggested their possible
correlation with the expression levels of miR-124 and miR-
155. Expression levels of the RANKL and BGLAP were
found to be significantly decreased (𝑃 < 0.05), whereas the
expression level of the OPG was found to be significantly
increased (𝑃 < 0.05) in NaF treated HOS cells. At lower
dose level, fold change in the expression levels of the RANKL,
BGLAP, and OPG was observed to be −2.85 (±0.18), −2.1
(±0.20), and 2 (±0.24), respectively. At higher dose level, fold
change in the expression levels of the RANKL, BGLAP, and
OPG was observed to be −2.04 (±0.16), −1.5 (±0.14), and 1.5
(±0.02), respectively (Figure 5).
Effects of sublethal concentrations of NaF on the expres-
sion profiles of 347 C/D box snoRNAs were analyzed using
a quantile approach. C-box (UGAUGA) is typically located
near the 5󸀠 terminal of snoRNA, whereas the D-box (CUGA)
is located in proximity of 3󸀠 terminal. The identification
of C/D box targets is quite different from miRNAs target
screening. Identification of C/D box targets relies on the elu-
cidation of putative methylation or pseudouridylation sites
at chromosome level. Total snoRNA probes with different
lengths (48–237 bp) were analyzed using an outlier analysis
(Supplementary data; S3A). The upper length threshold of
snoRNA probe was fixed to l ≥ 112.87. We have separately
analyzed the statistical outliers in order to investigate their
putative functions. Outlier analysis revealed 15 snoRNAswith
different lengths ranging from (114–237 bps) (Supplementary
data; S3B). In order to check the homogeneity of the longer
C/D box snoRNAs, the average two-parameter kimura’s
distance was estimated for the putative outliers set (⟨K2p⟩ =
0.184) (Supplementary data; S3C). Further analysis revealed
differential distribution of C-box and D-box (Supplementary
data; S3D). Each snoRNA sequence, except U22 and U97,
was found to contain one C-box, whereas numbers of D-box
in the given set were found vary between 0 and 5. Majority
of the length outliers (l > 112.87) of snoRNAs with two or
more D-box sequences were found to be downregulated in
NaF treated HOS cells compared to control. On the contrary,
snoRNAs with less than two D-box sequences were found to
be upregulated in NaF treated HOS cells compared to control
(data not shown). Compared to CG dinucleotides, higher
numbers of UG dinucleotides were found in the sequences of
all outliers. Single channel microarray exploratory protocol
analysis revealed up- and downregulation of C/D snoRNA
dataset, including length outliers and without outliers (Sup-
plementary data; S3E). 14qII-13 snoRNA was found to be
downregulated at both the sublethal concentrations of NaF
when analyzed with and without length outliers. 14qII-9,
HBII-85-1, U42B, U53, U73b, and U84 snoRNAs were found
to be upregulated at both the sublethal concentrations of
NaF when analyzed with length outliers. In the dataset
cleaned after outliers, the analyzed expression level of U58A
snoRNAwas found to be downregulated at both the sublethal
concentrations of NaF, whereas at the same condition the
expression levels of 14qII-9, HBII-336, HBII-52-7, U36B, U43,
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Figure 2: A Screen shot of Hcl clustering expression image of miRNAs. Red color shows overexpressed miRNAs (>0) and blue color shows
underexpressed miRNAs (<0). The hcl heat map image has been generated on the basis of log2 normalized intensity value. Here, C1 and C2
represent controls. 1 5 and 1 2 represent 8mg/L and 20mg/L NaF concentrations, respectively.
and U46 snoRNAs were found to be upregulated at both
the sublethal concentrations of NaF. Rest of the snoRNAs
(Supplementary data; S3E) were specifically expressed at
either of the sublethal doses of NaF.
4. Discussion
At present, no successful therapeutics is available to treat flu-
orosis [2]. Available therapies against fluorosismostly include
supplementations (cofactor of enzymes, amino acids, and
antioxidants) that can stimulate osteoblast/osteoclast medi-
ated bone formation and remodeling processes, macrophage
activation, and inhibition of reactive oxygen species (ROS)
[2, 3]. However, the therapeutic effects incurred due to these
therapies are not consistent. Reversals of the therapeutic
effects are often seen once the medication is discontinued
[2]. It is because these medications do not have control
on the epigenetic modifications that are responsible for
posttranscriptional regulation of genes involved in the osteo-
clastogenic pathway. Therefore, aim of the present study was
to find out epigenetic modifications in miRNAs and C/D
box snoRNAs that can regulate the key genes involved in the
development of fluorosis.
Noncoding RNAs are known to regulate majority of
the genes involved in the cellular pathways [9, 13, 14, 19].
Different xenobiotic compound may have different effects
on the expression profiles of noncoding RNAs [19]. In the
present study, sublethal concentrations of NaF were found
to induce alterations in the expression profiles of noncoding
RNAs (Figure 2). Functional targets of selected miRNAs
(miR-124 andmiR-155) were identified usingmirTarBase and
in silico hybridization analysis. Seed regions of the miR-124
and miR-155 displayed in silico hybridization with untrans-
lated regions (UTRs) of the RUNX2. miR-124 displayed in
silico hybridization with 3󸀠 untranslated regions of RANKL
(Figure 3). Further validation through quantitative RT-PCR
showed that the expression profiles of the miR-124 and miR-
155 were inversely proportional to the expression profiles of
the RUNX2 and RANKL genes. Thus, it can be inferred that
miR-124/miR-155 could be involved in the posttranscriptional
6 BioMed Research International
S
S
A A
A
C C
C
C C C
C
C
K C
C
C
CG
G G
G G
G G G
G
R
R
R
R
U U
A A A
A
A
A
AA AU U
U U
U U
U U
U
U
UU
U
U
A
U
G GW
W
W
Y
Y
3
󳰀
5
󳰀
miR-155
Se
ed
 re
gi
on
Seed region
miR-124
C
C
C
C
K
C
C
C
C
C
C
C
CR
C
C
C
C
G
G
G
G
G
G
G G
G
G
G
G
G
Y
G
G
G
M
B
B
B
Y
Y
Y
R
R
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
U
U
U
U
U
U
U
U
U
U
a
UK
W
W
W
U
U
U
U
S
Y
Y
c
c
c
c
hsa-miR-155/RUNX2 alignment
hsa-miR-124/RUNX2 alignment
hsa-miR-124/RUNX2 alignment
hsa-miR-124/TNFSF11 alignment (RANKL)
mirSVR score: −0.1710
PhastCons score:
mirSVR score:
PhastCons score:
mirSVR score:
PhastCons score:
mirSVR score:
PhastCons score:
0.5879
−0.0118
0.6612
−0.0205
0.7163
−0.0976
0.6817
3󳰀 uggggaUAGUGCUAAUCGUAAUu
3194: 5󳰀 cauggaAACACGA--AGCAUUAg
ccguaaguggcgcACGGAAu
caucccuaaaaccUGCCUUc
3󳰀 RUNX2
5󳰀 hsa-miR-155
3󳰀
715: 5󳰀 3󳰀 RUNX2
5󳰀 hsa-miR-124
ccguaaguggcgcACGGAAu
aaauuaaaauggaUGCCUUg
3󳰀
754: 5󳰀 3󳰀 TNFSF11
5󳰀 hsa-miR-124
ccguaaGUGGCG-CACGGAAu
cucuaaCACAGCUUUGCCUUc
3󳰀
1167: 5󳰀 3󳰀 RUNX2
5󳰀 hsa-miR-124
Figure 3: In silico hybridization analysis of mIR-124 and mIR-155 with the RUNX2 and RANKL.
regulation of the RUNX2 and RANKL in NaF exposed HOS
cells.
Yin et al. (2010) studied role of miR-155 in regulation
of BMP signaling pathway and demonstrated that miR-
155 binds to 3󸀠UTRs of target mRNAs and regulates the
expression of key genes involved in BMP signaling pathway
(RUNX2, SMAD1, SMAD5, HIVEP2, CEBPB, and MYO10)
[10]. Further studies on knockout model demonstrated
that miR-155 can directly inhibit BMP signalling pathway
[10].
RUNX2 is an osteoblastic transcription factor that medi-
ates osteoblast and osteoclast signaling pathway during bone
formation and bone resorption [20]. Otto et al. reported
that RUNX2 inhibition resulted in the death of new born
null mouse due to the disfunctioning of bone formation and
skeletal mineralization pathway [21]. Our results correspond
with investigations on mice, which reported decrease in level
of RUNX2 after NaF exposure [5, 22].
Significant decrease in expression levels of the RANKL
was observed in NaF treated HOS cells (Figure 5). Simi-
lar results were reported in Xenopus laevis and B6 mice
when exposed to sodium fluoride [5, 22, 23]. RANKL, a
transmembrane protein, expresses on the osteoblast cells
[6]. RANKL binds to its receptor (RANK) present on the
progenitor osteoclast and stimulates osteoclastogenesis [6].
RANK-RANKL binding activate downstream target genes
(TRAF6, NF-𝜅𝛽, and C-fos) in RANK signaling pathway
[4, 7, 8]. RANK-RANKL signaling facilitates phagocyte
activation, osteoclast maturation, and bone resorption [4, 7,
8, 24]. Osteoclast at the end of remodeling step undergoes
apoptosis via phagocytosis [4–8]. This results in the release
of calcium in blood which assists the bone mineralization
process. Available literature entails that RUNX2 acts as a
transcription factor of RANKL [7], whereas our results based
on qPCR and in silico hybridization analysis revealed that
miR-124 can be involved in the direct regulation of RANKL
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(Figures 3, 4, and 5). Thus, it can be seen that miR-124/miR-
155 can regulate the RANKL expression either through the
direct binding of miR-124 with the RANKL untranslated
regions or via RUNX2 mediated transcriptional inactivation.
Compared to the higher dose of NaF (20mg/L), elevated
levels of miR-124 and miR-155 expressions were seen at
lower dose level of NaF (8mg/L). It has been reported that
fluoride exposure may have biphasic effect on osteoblast and
osteoclast cells [2]. Fluoride exposure at lower concentration
promotes bone development, whereas exposure to higher
concentration of fluoride may lead to cellular stress [2].
Thus, the higher expression levels of miR-124 and miR-155 at
lower concentrations of NaF (8mg/L) obtained in our study
could be attributed to the biphasic effects exerted by NaF.
Compared to the higher dose level, elevated expression levels
of miR-124 and miR-155 at lower dose of NaF resulted in
the higher degree of differential expression of genes (RUNX2,
RANKL, BGLAP, and OPG) involved in the osteoclastic
differentiation.
Normal RANK-RANKL signaling provides proper struc-
ture and mechanical strength to bones [5, 6, 22]. However,
study on various animal models suggests that increase in
RANKL-RANK interaction resulted in osteoporosis, exces-
sive loss of bone [24]. To regulate the interaction network
between RANK-RANKL, osteoblast cells secret a soluble
decoy of RANKL called OPG [23, 24]. Thus, excessive loss of
bone can be preventedwhenOPGbinds to RANKL and inter-
feres with osteoblast and osteoclast interactions [23]. OPG
and RANKL are synthesized by osteoblast cells. Decrease
in RANKL or increase in OPG may result in osteopetrosis
[23, 24]. In our study, OPG was found to be significantly
upregulated, whereas the RANKLwas found to be downregu-
lated after NaF exposure to HOS cells (Figure 5). Thus, it can
be seen that the sublethal concentrations of NaF can cause
aberrant changes in the RANKL/RANK/OPG system. qPCR
analysis revealed that the sublethal concentrations of NaF can
downregulate the expression levels of BGLAP (osteocalcin)
(Figure 5). Osteocalcin plays an important role in the process
of bonemineralization, energymetabolism, and bone remod-
eling [25]. Carboxylated osteocalcin is involved in formation
of calcium hydroxyapatite crystals which are deposited in the
triple helical fibrils space of bone matrix [26]. Excess intake
of fluoride may result in the downregulation of osteocalcin.
It results in the conversion of calcium hydroxyapatite crystals
to fluorapatite crystal [25, 26]. As a result, bones become
stiff and loss its mechanical strength. Low concentration of
osteocalcin can affect the expression of insulin and prolif-
eration of 𝛽-cells [27]. This may limit leptin (secreted by
adipocytes) mediated PTH (parathyroid hormone) release
from parathyroid glands [27]. Low levels of PTH blocks
1-hydroxylase mediated upregulation of calcitriol (vitamin
D) in the kidney [28]. As a result, process of absorption
of dietary calcium in the small intestine and secretion of
free calcium (via apoptosis of osteoclast) required for the
RANKLmediated bone formation and remodeling is severely
hampered (Figure 6) [27, 28].
Compared to CG dinucleotides, outlier analysis of C/D
box snoRNAs revealed higher numbers of UG dinucleotides
after NaF exposure to HOS cells. Spontaneous deamina-
tion of unmethylated cytosine residues of CG dinucleotides
may result in the conversion of cytosine to uracil residues
[13]. Deamination reaction is caused due to hydrolysis of
cytosine [19]. Fluoride ion, being highly electronegative,
can cause hydrolysis of water molecules inside the cellular
environment. In this regard, the possibility of spontaneous
deamination of unmethylated cytosine after the exposure of
NaF cannot be denied.
Compared to the terminal C/D box, microarray analysis
revealed more marked effect of fluoride exposure on the
expression levels of internal C/D boxes of snoRNAsThe C/D
boxes snoRNAs are short ncRNAs that are mainly involved
in RNA editing processes leaded by ADAR proteins. In
particular the C/D box snoRNAs are prominently involved
in methylation processes, at 2-O-ribose position of different
cellular RNAs. Their name derives from the presence of
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Figure 6: miRNA mediated alterations in bone formation and remodeling pathway.
two conserved nucleotide stretches: the C-box (UGAUGA)
displaced near the 5 termini and the D-box (CUGA) located
in proximity of 3 termini [29]. Many evidences support that
one of the critical events, associated with environmental
stress, is the alteration of methylation processes at DNA or
RNA level. Recent studies have underlined the criticality of
RNAmethylation biological process such as cell stability [12].
Schroeder et al. reported that metal ions or binding
proteins are responsible for stabilizing the minor grooves of
the canonical and noncanonical stems of C-box and D-box
motifs [30]. In this regard, longer C/D box snoRNAs may
contain additional nucleotide motifs that can interact with
themetals and other binding proteins and influence the func-
tional role of these molecules. Deschamps-Francoeur et al.
reported that snoRNA displaying long ends (snoRNAL) were
overexpressed in ovarian and breast cancer cell lines, whereas
snoRNA displaying short ends (snoRNASH) were abundant
in normal cell lines [31]. Furthermore, snoRNAL were mostly
found to display canonical snoRNA features compared to
noncanonical features found in snoRNASH. C/Dbox snoRNA
may have an additional internal D-box in the middle of
the molecule. Addition of internal D-box motifs can affect
(1) hairpin structure formation of 5󸀠 and 3󸀠 motifs of C-
box and D-box elements; (2) binding with contaminants;
(3) expression of other noncoding RNAs. Thus, it can be
stated that the conformational differences due to presence of
varying numbers of C-box and D-box sequences may alter
the functional motifs of C/D box snoRNAs.
BioMed Research International 9
Length outlier analysis showed high numbers of D-
box containing snoRNAs in NaF treated HOS cells when
compared to the numbers of C-box containing sequences
(Supplementary data; S3D). Downregulation of C/D box
length outliers with more numbers (≥2) of D-box sequences
in NaF treated HOS cells suggest the possible interactions of
NaFwith snoRNAs due to conformational alterations exerted
by additional D-box sequences. Microarray analysis revealed
that sublethal concentrations of NaF can induce mark dif-
ferences in the expression profiles of snoRNAs in HOS
cells (Supplementary data; S3E). Structure of differentially
expressed snoRNAs, their function, and reports on their pos-
sible interactions with osteoclastic pathway is given in Sup-
plementary data S3F. Till date no reports are available on the
possible interaction of snoRNAs in the osteoclastic pathway.
D-box has a vital role in the methylation of ribosomal
RNA (rRNA) [32]. D-box recognizes the nucleotide of rRNAs
to be methylated (usually 5th nucleotide upstream from the
D-box binding site) [32, 33]. These results suggest that NaF
can affect snoRNA mediated methylation of 28 s ribosomal
RNA. This may result in the activation of aberrant transcrip-
tional cascades involved in osteoclastogenic pathway. The
present study was carried out only on a limited set of C/D box
RNAs. This preliminary in silico analysis could be extended
to whole set of currently identified C/D box RNAs for the
further validation of the results obtained in this study.
5. Conclusion
Effect of fluoride on the epigenetic modifications is not
yet reported. Herein, we report the direct/indirect possible
interactions of mIR-124 and mIR-155 with the RUNX2 and
RANKL in NaF treated HOS cells. Obtained results suggest
that mIR-124 and mIR-155 can be considered the new players
involved in the development of fluorosis. In addition, our
results imply the possible role of C/D box snoRNAs in the
development of fluorosis. However, these results need to be
validated with the other in vitro and in vivo models. Future
studies should be designed on the possible role of miRNAs
(mIR-124 and mIR-155) and snoRNAs in the development of
fluorosis and their implications as the possible therapeutic
drug targets against fluorosis; in particular it is important
to plan experiment to investigate the interactions between
fluoride and proteins involved in the methylation cascade
or in the miRNA dicer dependent and dicer independent
biogenesis pathways.
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